News

The Phase III clinical programme include two 12-week randomized, placebo-controlled efficacy studies (with approximately 630 randomized patients each) and an open-label, randomized, long-term safety study with a ‘usual

Under the terms of the agreement, Novartis will receive exclusive rights to an undisclosed family of oncology compounds discovered and owned by Nerviano. Novartis will have responsibility to

Earlier in January 2011, Plexxikon has started patient recruitment in first of two Phase 1 clinical trials with PLX5622. The initial Phase 1 trial is a single-ascending dose

Nanopore-specific data analysis pipelines for Pipeline Pilot will be offered as the preferred and supported solution for secondary and higher level data analysis for the Oxford Nanopore DNA

As per the new agreement, Cortex will make an upfront payment to Biovail of $200,000, and potential future payments of up to $15.15m based on the achievement of

Tamiflu is FDA Approved for the treatment of uncomplicated acute illness due to influenza infection in patients one year or older who have been symptomatic for no more

Intralytix has received clearance in the form of a ‘Food Contact Notification’ or FCN, filed with the FDA specific for the use of EcoShield on red meat parts

The SMN ELISA kit will enable and expedite drug discovery, development and therapy for Spinal Muscular Atrophy, a genetic cause of mortality in infants and toddlers. The SMN

As per the terms of the agreement, Boehringer Ingelheim has taken responsibility to develop and commercialize the products and it will pay a sum of $12.5m license fee